INTRODUCTION
Interstitial extracellular matrix (ECM) accumulation, common to many chronic kidney diseases, contributes to functional loss. Kidney interstitial fibrosis can be defined as the accumulation of collagen and related molecules in the interstitium. Interstitial collagen is normally present in the kidney, particularly type I and III, which serves as structural scaffolding [1 & ,2 & ]. This review addresses mechanisms by which interstitial fibrosis arises, shown through animal experimentation and analysis of human kidneys. In addition, approaches to assess interstitial fibrosis are considered.
Interstitial fibrosis patterns differ and probably do not have identical causes or consequences. Broad scars with tubular loss are the sequelae of severe focal injury and parenchymal destruction, such as in pyelonephritis and infarcts [3] . This pattern is no doubt a 'wound healing' response to repair integrity loss and prima facie beneficial to renal function. In contrast, a second pattern (far more common in renal biopsies) is diffuse or patchy fine interstitial fibrosis, surrounding either atrophic or normal tubules and associated with either diffuse or focal disease of glomeruli, tubules, or vessels [4, 5] . Many studies show a reciprocal correlation between kidney function and the interstitial fibrosis extent [6 & ,7-10,11 & , [12] [13] [14] . Tubular atrophy is defined as loss of specialized transport and metabolic capacity and typically manifested by small tubules with cells with pale cytoplasm or dilated, thin tubules. Tubular atrophy is usually associated with interstitial fibrosis (often abbreviated to IFTA); but probably has distinct mechanisms related to blood flow, glomerular filtration rate (GFR) or tubular continuity loss. However, interstitial fibrosis and tubular atrophy are separable, as shown by the profound tubular atrophy in renal artery stenosis, which characteristically has little or no fibrosis (or inflammation) [3] .
CELLULAR AND MOLECULAR MEDIATORS
Interstitial fibrosis and tubular atrophy results from an orchestration of multiple cell types, as detailed below (Table 1 , Figs 1 and 2).
Fibroblasts and myofibroblasts
Fibroblasts constitute a large proportion of renal interstitial cells and are the major cell-maintaining constituent of ECM, which can be considered the kidney 'skeleton'. Fibroblasts lack a cell type-specific marker, making their study difficult [1 & ]. Fibroblasts are distinguished from other interstitial cells by their abundance of rough endoplasmic reticulum, prominent F-actin cytoskeleton, and by ecto-5 0nucleotidase expression in their plasma membrane. Fibroblasts interact with other cells, such as dendritic cells, through cell processes [17] . Fibroblasts may acquire a myofibroblastic phenotype under paracrine signals after attaching to injured tubular basement membranes (TBMs), [18] [19] [20] [21] , eventually producing collagen type III [22] . This hypothesized phenomenon is likely a crucial event in interstitial fibrosis [1 & , 23, 24] . Myofibroblasts express smooth muscle actin (SMA), contain microfilaments with focal densities (stress fibers), peripheral myofilament condensations known as fibronexi connecting actin microfilaments with extracellular fibronectin, round nuclei, and frequent attachments to basement membranes [17, 25, 26] . Myofibroblasts also contain vimentin, fibronectin with the splice variant containing ectodomain A [17, 20] , and S100A4 (also known as FSP-1) [17, 22] ; S100A4, once considered myofibroblast specific, also colocalizes with some leukocytes [17, 22] . Interstitial myofibroblasts have multiple potential origins, with candidates being fibroblasts, pericytes, perivascular cells [22, [27] [28] [29] [30] [31] [32] , and endothelial cells [33, 34] .
Fibrocytes
Fibrocytes, thought to be distinct from fibroblasts, are spindle-shaped, ECM-producing cells derived from peripheral blood leukocytes [35] . Both hematopoietic (e.g. CD45) and stromal cell (e.g. type I collagen) markers can be detected on fibrocytes; and furthermore, these cells also express chemokine receptors. Fibrocytes are found in injured kidneys, possibly through in-situ differentiation or infiltration through chemokine gradients [36] [37] [38] . T-helper-2-type (T H 2) cytokines appear to be profibrotic, inducing differentiation of human fibrocytes; and in contrast, T-helper-1-type (T H 1) cytokines can inhibit differentiation of fibrocytes [36, 39, 40] . Fibrocytes may be affected by drugs such as cyclosporine which induces type I collagen, possibly explaining IFTA attributed to chronic calcineurin inhibitor toxicity [36] . Fibrocytes are present in systemic nephrogenic fibrosis, related to gadolinium administration [41] .
Extracellular matrix
Multiple ECM components apart from collagen have a crucial role in interstitial fibrosis [42] [43] [44] [45] [46] . Tissue transglutaminase (tTG) expression is increased in animal and human renal disease models, correlating with interstitial fibrosis severity; and tTG cross-links proteins, stabilizing ECM and conferring resistance to protease degradation [47] [48] [49] . Matrix metalloproteinase (MMP) enzymes are proteolytic enzymes that can degrade all matrix
KEY POINTS
Interstitial fibrosis and tubular atrophy formation results from a complex cellular and molecular milieu participating in extracellular matrix formation.
Molecular mediators involved are numerous and involve pathways such as transforming growth factor (TGF)-b, bone morphogenic protein (BMP), plateletderived growth factor (PDGF), and hepatocyte growth factor (HGF); and important cells include epithelial cells, fibroblasts, myofibroblasts, fibrocytes, endothelial cells, lymphocytes, monocyte/macrophages, dendritic cells, and mast cells.
Epithelial and endothelial cells may undergo transition to mesenchymal cells; however, this research may simply indicate transition to a phenotype rather than an actual cell type transition.
protein components [50] . Tissue plasminogen activator (tPA), although proteolytic, increases interstitial fibrosis development by inducing MMP-9 gene expression, leading to TBM disruption and epithelial mesenchymal phenotype promotion [51] . Mice without the MMP-9 gene have less IFTA in obstructive nephropathy [50] . Plasmin, a serine protease, can activate MMPs, leading to ECM degradation and reduced interstitial fibrosis [52] [53] [54] . Decreased laminin, a component of glomerular and peritubular capillary (PTC) basement membranes, leads to more IFTA [55, 56] . ECM production is also affected by the renin/angiotensin system [57] [58] [59] [60] [61] [62] [63] [64] .
Tubular epithelial cells
Tubular epithelial cells (TECs) are postulated to contribute to increased ECM through the process of epithelial-to-mesenchymal transition (EMT), defined as the stepwise loss of epithelial markers, such as E-cadherin, and the acquisition of mesenchymal markers, such as vimentin and SMA [1 & ,65,66]. As an ultimate step in EMT, cells acquire increased motility and traverse basement membranes into the interstitium [67] . Convincing experimental evidence for epithelial cell migration into the interstitium has been acquired in interstitial fibrosis in mouse kidneys, where the origin of the cells can be followed with indelible genetic markers [2 & ,67]. A similar in-situ change in tubular epithelial phenotype occurs in humans, but emigration of TECs into the interstitium has not been demonstrated. Therefore, many question the migration feature of EMT [68 && ,69,70] . A recent Banff Conference symposium on EMT concluded that the in-situ epithelial response exists but needs a name that does not imply emigration of tubular cells to the interstitium, [71] which we will here term 'epithelial mesenchymal phenotype' (EMP). Tubular epithelial cells clearly undergo marked phenotypic changes in acute injury [72] and appear to provide key signals to induce interstitial fibrosis [1 & ]. Intratubular stretch, fluid shear stress, and biomechanical forces modify intracellular signaling and gene expression, contributing to interstitial fibrosis [18] . EMP is supported by the finding of increased intermediate filaments (e.g. vimentin and nestin) in injured tubular epithelium [73, 74] , an association with increased collagen type I and III expression in TECs, [75] and altered E-cadherin expression [76] . Transcription factors such as the zinc-finger transcription factor snail homolog 1 (Snai1) [77] , which interacts with the notch signaling pathway [78] , appear to be important to EMP. An important component in the regulation of genes in EMP and interstitial fibrosis may include micro(mi)RNAs [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] , some antifibrotic [89] and others profibrotic [90 & ]. Autophagy, the process whereby cells undergo 'self digestion' [1 & ,91,92], and endoplasmic reticulum stress are important to IFTA [93] [94] [95] [96] [97] [98] [99] . TECs may undergo damage through the increased action of lipids in a 'lipid nephrotoxicity' process, mediated in part by peroxisome proliferator-activated receptor (PPAR) expression [100] [101] [102] [103] [104] [105] [106] .
Vascular endothelial growth factor (VEGF)-A overexpression in tubular cells can result in increased serum VEGF levels, leading to increased capillary number and size, type IV collagen deposition, and fibroblast and myofibroblast numbers [107] . However, other studies show that VEGF administration may decrease interstitial fibrosis [108] . Hypoxia promotes fibrosis through multiple mediators including hypoxia-induced factor-1a (HIF-1a) [109] [110] [111] [112] .
Epigenetic modification through methyltransferase Dnmt1 hypermethylation of the Ras oncogene inhibitor RASAL1 decreases interstitial fibrosis 113, 114] . Another chromatin structure modifier, histone deacetylase (HDAC), modulates proinflammatory and fibrotic changes in tubulointerstitial injury, [115, 116] and histone methylation may also be important in fibrotic gene expression [117] . Growth arrest may lead to renal injury through increased fibrosis, characterized by an increased proportion of TECs in phase G2/M, which gives the cells a profibrotic phenotype, in large part mediated by c-Jun N-terminal kinase signaling. Pharmacologic induction of growth arrest can promote fibrosis [118] .
Inflammatory cells
Numerous inflammatory cell types contribute to IFTA, as discussed below.
Lymphocytes
Lymphocytes appear to have important roles in the genesis of IFTA [119] [120] [121] . CD4þ T cells are considered particularly crucial to this process, since CD4þ but not CD8þ lymphocyte reconstitution increased interstitial fibrosis in recombinase activator gene knockout mice and CD4þ depletion decreased interstitial fibrosis [119] . A recent microarray analysis of renal allografts showed increased T-cell and natural killer gene sets in IFTA development [122 & ]. High T-cell and macrophage but not B-cell infiltration is associated with low IL-10 expression, which conferred susceptibility to IFTA [123] .
Monocyte/macrophages
Monocyte/macrophages are heterogeneous, and some are profibrotic, [124, 125] particularly CD11bþ cells [126, 127] . Galectin-3 (Gal-3) is a b-galactosidase-binding lectin released from macrophages that acts as a profibrotic mediator [127] . Gal-3 may protect renal tubules from chronic injury by enhancing ECM remodeling and attenuating fibrosis [128] . The macrophage growth factor, CSF-1, is released by renal tubular cells, leading to repair and reduced interstitial fibrosis [129] . Models constructed to investigate the role of macrophages in interstitial fibrosis include: adriamycin-induced nephropathy [130] , cyclophosphamide depletion of macrophages [131] , and adoptive transfer of bone marrow-derived macrophages [131, 132] . The role of macrophages in interstitial fibrosis is clearly complex, since some subsets of bone marrow-derived monocytes may actually attenuate fibrosis [132] .
Dendritic cells
Dendritic cells are present in substantial numbers in the renal interstitium [17] , and recent studies have shown their importance in interstitial fibrosis. Dendritic cell depletion through injection of diphtheria toxin in transgenic mice with a CD11c/diphtheria toxin receptor may ameliorate interstitial fibrosis [133, 134] . Other studies show that dendritic cells act indirectly, activating T cells to produce fibrosis [121] .
Mast cells
Mast cells are a component of the primary innate immune system and are typically infrequently found in normal kidneys, often congregating around vessels and epithelium. Increased mast cell numbers have been associated with profibrotic roles [135] [136] [137] [138] [139] , inversely correlating with renal function [137, 139, 140] . Mast cell deficiency has been associated with decreased fibrosis [137] . Mast cells have also been associated with antifibrotic actions [141] .
Endothelial cells, peritubular capillaries, and vascular supply
Experimental evidence supports the view that endothelial cells contribute to interstitial fibroblasts, possibly through a process of EMT [23, 31, 33, 35, [142] [143] [144] [145] . PTCs decrease with time in allografts and are inversely related to renal function; decreased PTC density at 3 months predicts later loss of function at 1 year [146 & ]. Kidney lymphatic vessels are important in facilitating inflammatory cell emigration. Interstitial fibrosis is associated with increased lymphangiogenesis, partly driven by VEGF-C [147] . Angiogenesis and inflammation inhibition with sirolimus can prevent interstitial fibrosis [148] . Newly formed lymphatics may be found close to glomeruli with tuft adhesions [147] , perhaps participating in the misdirection of urine filtrates in these areas [149] . Other studies have found a connection between lymphangiogenesis, tissue remodeling, and differential proteoglycan expression [150] . Lymphangiogenesis occurs as early as 72 h after transplantation and tends to correlate with inflammation [151] .
Molecular mediators and signaling pathways
Transforming growth factor-b (TGF-b) is regarded as a central mediator of interstitial fibrosis (Table 1) 47, [152] [153] [154] [155] [156] [157] . TGF-b up-regulation occurs in nearly every chronic kidney disease (both human and animal). TGF-b, possibly one of the most widely studied regulators of ECM production, is produced in a latent form, TGF-b1, bound to latency-associated peptide (LAP), which inhibits TGF-b receptor binding. Latent TGF-b-binding protein (LTBP) binds this complex and inhibits binding to the ECM [158, 159] .
TGF-b acts through Smad for downstream signaling [160] [161] [162] , which is amplified if Smad antagonists (e.g. SnoN and Ski corepressors) are lost [163] [164] [165] . Resulting fibrogenic signals stimulate fibroblasts, presumably initiating tubular EMP. TGF-b also works through the jagged/notch pathway, which may be inhibited to decrease fibrosis [166] [167] [168] , and Crim1, which binds and regulates TGFb-2, VEGF, and PDGF-b to decrease fibrosis [169] .
Bone morphogenic protein (BMP), particularly BMP-7, acts as a natural TGF-b antagonist; and due to this, BMP may have renoprotective effects and may possibly reverse interstitial fibrosis [163, [170] [171] [172] . Sclerostin domain-containing protein 1 [also known as uterine sensitization-associated gene 1 (USAG-1)] is an endogenous inhibitor of BMP- 47, 173, 174] . Inhibiting the circulating proteolytic enzyme BMP1-3 (a tolloid-like proteinase) reduces interstitial fibrosis [175, 176] .
Toll-like receptors (TLRs) participate in IFTA [177, 178] . TLR4 modulates IFTA susceptibility through the BAMBI (BMP and activin membrane bound inhibitor), a negative regulator of TGF-b, attenuating tubular injury but promoting interstitial fibrosis [178] ; however, other studies fail to show TLR influence [179, 180] .
TGF-b activation blockade can be accomplished with decorin antisense TGF-b expression inhibition, neutralizing TGF-b antibodies and soluble TGF-b receptors [181] . Small molecule inhibitors to TGFb are being developed [182] . However, it is difficult to ascertain whether TGF-b inhibition will be universally useful in inhibiting fibrosis. TGF-b also has anti-inflammatory properties; and there is concern that TGF-b inhibition could lead to increased inflammation and thus fibrosis [182] . TGF-b action may also be mediated by reactive oxygen species and oxidative damage [183] .
The TGF-b-inducible integrin aVb6 appears to be restricted to epithelial cells in which it is normally expressed in renal tubules at low levels and elevated during injury, development, and neoplasia. This integrin appears to have a role in increasing interstitial fibrosis and inflammation [184] . Integrin-linked kinases have associated with increased IFTA, corresponding with increases in collagen IV and TGF-b [185] .
Hepatocyte growth factor (HGF) is considered to be an antifibrotic factor with effects opposite TGF-b, blocking Smad2/3 nuclear translocation in interstitial fibroblasts, inhibiting tubular EMP. Administration of HGF or its gene can decrease interstitial fibrosis observed in animal models [186] [187] [188] . However, long-term proteinuria has been demonstrated with HGF administration [189] .
Platelet-derived growth factor (PDGF), comprising four isoforms (PDGF-A, B, C, and D) and two receptor chains (PDGFR-a and b), appears to have an important role in interstitial fibrosis [25, 190] . PDGF-C, a, and CC are noteworthy contributors to the renal cortical interstitium [1 ]. Complement inhibition or lack of complement components appears to be antifibrotic [195, 196] . Proteomic data indicate contributions from the alternative rather than the classic complement pathway to IFTA [197] .
EVALUATION OF INTERSTITIAL FIBROSIS
Interstitial fibrosis extent is predictive of renal allograft outcome and may be considered a surrogate IA; CIII IHC IF measurements by a semiautomatic system correlate with GFR in protocol renal transplant biopsies GFR correlated negatively with interstitial volume fraction at 6 months (P ¼ 0.05) [13] marker [198] [199] [200] [201] [202] . Several applications require accurate interstitial fibrosis measurement [6 & ,7-14, 26,171,202-213] including research focused on therapeutic inhibition of interstitial fibrosis and comparison of renal allograft protocol biopsies [47, 182, 214, 215] . Visual assessment of trichromestained slides is often standard institutional practice [216] , but studies have shown this approach may have poor reproducibility [217, 218] . Several morphometry techniques are used to assess interstitial fibrosis ( Fig. 3) , including morphometry of slides stained with trichrome [10, 204] ; Sirius Red, specific for collagen types I and III under polarized light [26, 208, 219] ; and collagen immunohistochemistry, particularly type III collagen [12, 220, 221] . Computer-assisted morphometry has shown utility in the analysis of studies employing trichrome, Sirius Red, and collagen III immunohistochemistry; and analysis in some of these studies has shown correlation with glomerular filtration rate [6 & ,8,11 & ,12, 26,171,204,208,219-224] (Table 2) .
There are intrinsic limitations in the measurement of interstitial fibrosis, some of which are due to sampling. For example, one study estimated that repeat biopsies show a decrease in the measured level of fibrosis, presumably due to sampling, in 12% of cases [225] . In addition, not all fibrosis is 'equal' or the 'same' in quality and thus aggregate quantity. For example, 'active' or 'young' interstitial fibrosis may have greater potential for remodeling. Broad scars may have different consequences than diffuse, fine interstitial fibrosis. Inflammation in areas of interstitial fibrosis has also been noted in several studies to be an adverse risk factor for progression of renal disease [20, 202, [225] [226] [227] [228] [229] .
Overall, there is no consensus regarding the best way to assess interstitial fibrosis. Efforts to reach a consensus or at least provide recommendations are currently underway under the auspices of the Banff Conference on Allograft Pathology [230] .
CONCLUSION
Molecular mechanisms leading to IFTA are complex and typically inter-related with the primary processes leading to renal injury. Further elucidation of these mechanisms could lead to targeted inhibitors to alleviate terminal scarring. Furthermore, there are a number of ways to assess fibrosis, and efforts are underway to improve these methods.
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